INCB053914 was generally well tolerated as monotherapy and in combinations; TEAEs were most commonly ALT/AST-elevated. Limited responses were observed with combinations. Future studies are needed to identify rational, effective combination strategies.

1 year ago

P1/2 data • Clinical Trial,Phase II • Journal • Combination therapy • Metastases

cytarabine • azacitidine • Jakafi (ruxolitinib) • uzansertib (INCB53914)

over3years

Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov)

P1/2, N=97, Completed, Incyte Corporation | Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2020 | Trial primary completion date: Jan 2021 --> Jul 2020

over 3 years ago

Clinical • Trial completion • Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2)

cytarabine • azacitidine • Jakafi (ruxolitinib) • uzansertib (INCB53914)

over4years

Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov)

P1/2, N=97, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=270 --> 97

over 4 years ago

Clinical • Enrollment closed • Enrollment change

BCL2 (B-cell CLL/lymphoma 2)

cytarabine • azacitidine • Jakafi (ruxolitinib) • uzansertib (INCB53914)

over4years

Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov)

P1/2, N=270, Recruiting, Incyte Corporation | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021

over 4 years ago

Clinical • Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2)

cytarabine • azacitidine • Jakafi (ruxolitinib) • uzansertib (INCB53914)